WO2004064751A3 - Nanoparticle based stabilization of ir fluorescent dyes - Google Patents

Nanoparticle based stabilization of ir fluorescent dyes Download PDF

Info

Publication number
WO2004064751A3
WO2004064751A3 PCT/US2004/001472 US2004001472W WO2004064751A3 WO 2004064751 A3 WO2004064751 A3 WO 2004064751A3 US 2004001472 W US2004001472 W US 2004001472W WO 2004064751 A3 WO2004064751 A3 WO 2004064751A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
nanoparticle
fluorescent dyes
dyes
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/001472
Other languages
French (fr)
Other versions
WO2004064751A2 (en
Inventor
Mostafa Sadoqi
Jun Shao
Vishal Saxena
Sanil Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST JOHNS UNIVERSITY NEW YORK
Original Assignee
ST JOHNS UNIVERSITY NEW YORK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST JOHNS UNIVERSITY NEW YORK filed Critical ST JOHNS UNIVERSITY NEW YORK
Priority to EP04702592A priority Critical patent/EP1583473A2/en
Priority to US10/542,185 priority patent/US20070148074A1/en
Priority to CA002516116A priority patent/CA2516116A1/en
Publication of WO2004064751A2 publication Critical patent/WO2004064751A2/en
Publication of WO2004064751A3 publication Critical patent/WO2004064751A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention relates to a highly effective nanoparticle system for stabilizing near-infrared (near-IR) fluorescent dyes such as indocyanine (ICG) in order to enhance the dye's utility for biomedical application. This invention further relates to nanoparticles comprised of biodegradable polymer materials such as poly(dl-lactide-co-glycolide)(PLGA). The invention also relates to methods of preparing the nanoparticle-entrapped dyes, as well as methods for using them in bioimaging, diagnosis, and treatment of disease. The present invention also relates to compositions and kits comprising nanoparticle-entrapped dyes.
PCT/US2004/001472 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes Ceased WO2004064751A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04702592A EP1583473A2 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes
US10/542,185 US20070148074A1 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes
CA002516116A CA2516116A1 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44065803P 2003-01-16 2003-01-16
US60/440,658 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004064751A2 WO2004064751A2 (en) 2004-08-05
WO2004064751A3 true WO2004064751A3 (en) 2005-01-06

Family

ID=32771845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001472 Ceased WO2004064751A2 (en) 2003-01-16 2004-01-15 Nanoparticle based stabilization of ir fluorescent dyes

Country Status (4)

Country Link
US (1) US20070148074A1 (en)
EP (1) EP1583473A2 (en)
CA (1) CA2516116A1 (en)
WO (1) WO2004064751A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406462T1 (en) * 2004-08-18 2008-09-15 Hoffmann La Roche METHOD FOR MEASURING NUCLEIC ACID AMPLIFICATION IN REAL TIME INCLUDING THE POSITIONING OF A REACTION VESSEL RELATIVE TO A DETECTION UNIT
WO2006079091A1 (en) * 2005-01-24 2006-07-27 Mallinckrodt Inc. Methods of providing long-term stability to biocompatible optical dyes and bodily fluids
JP4982839B2 (en) * 2005-06-22 2012-07-25 国立大学法人京都大学 Vitreous visualization agent
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US7470731B2 (en) * 2005-06-24 2008-12-30 Pitney Bowes Inc. Fluorescent ink
EP1760467A1 (en) * 2005-09-02 2007-03-07 Schering AG Optically fluorescent nanoparticles
WO2007062207A2 (en) * 2005-11-23 2007-05-31 Schering Corporation Methods for quantifying polymer attachment to a particle
DE102006026203A1 (en) * 2006-05-31 2007-12-06 Carl Zeiss Microimaging Gmbh Method for spatially high-resolution imaging
EP2054087A2 (en) 2006-07-06 2009-05-06 The Trustees of Columbia University in the City of New York Polychromatic, diversely-sized particles for angiography
WO2008088586A2 (en) 2006-09-11 2008-07-24 William Marsh Rice University New phototherapeutic materials prepared through nanoparticle assembly
KR100925690B1 (en) * 2007-09-10 2009-11-10 한국생명공학연구원 Polymer particles containing near-infrared fluorescent die and manufacturing method thereof
EP2036577A1 (en) 2007-09-14 2009-03-18 mivenion GmbH Diagnostic materials for optical image-forming investigation based on nanoparticulate formulations
US20110275686A1 (en) 2009-12-11 2011-11-10 Biolitec, Inc. Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
US20130108552A1 (en) * 2010-03-01 2013-05-02 University Of Florida Research Foundation Inc. Near-ir indocyanine green doped multimodal silica nanoparticles and methods for making the same
US8758778B2 (en) 2010-09-16 2014-06-24 The Regents Of The University Of California Polymeric nano-carriers with a linear dual response mechanism and uses thereof
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
JP6204345B2 (en) 2011-03-23 2017-09-27 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ Compositions and methods for enhancing stem cell pluripotency
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US9932560B2 (en) 2011-05-13 2018-04-03 Elixirgen, Llc Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP2890372A4 (en) 2012-08-28 2016-01-27 Univ California POLYMERIC NANOSUPPORTS WITH RELEASE MECHANISM TRIGGERED BY LIGHT
EP3782628B1 (en) 2013-03-15 2024-08-07 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejuvenating human cells
KR102233251B1 (en) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 Novel nanoparticle compositions
US9915757B1 (en) 2013-06-24 2018-03-13 The Research Foundation For The State University Of New York Increased thermal stabilization of optical absorbers
AU2014340241B2 (en) 2013-10-21 2018-11-01 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
MX2016011517A (en) 2014-03-07 2017-04-13 Univ Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain.
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
CN105267965B (en) * 2015-10-15 2018-08-21 苏州杰纳生物科技有限公司 A kind of poly (lactic acid-glycolic acid) compound and preparation method thereof
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
CN108619515A (en) * 2018-07-10 2018-10-09 天津工业大学 A kind of preparation and application of the tungsten oxide and indocyanine green microballoon of PLGA claddings
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
CA3266235A1 (en) 2018-09-26 2025-11-29 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
WO2020072805A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
CN109799216B (en) * 2018-12-29 2021-11-12 佛山科学技术学院 Fluorescence OCT dual-mode imaging method and device based on green nano indocyanine
EP3921334A1 (en) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
WO2020185658A1 (en) * 2019-03-08 2020-09-17 North Carolina State University Photothermal therapy promotes tumor infiltration and antitumor activity of cart t cells
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CA3149164A1 (en) 2019-09-03 2021-03-11 Suma Krishnan Compositions and methods for the treatment of congenital ichthyoses
CA3160199A1 (en) 2019-12-20 2021-06-24 Suma Krishnan Compositions and methods for gene delivery to the airways and/or lungs
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
BR112023020209A2 (en) 2021-04-02 2023-12-19 Krystal Biotech Inc RECOMBINANT HERPES VIRUS GENOME, HERPES VIRUS, PHARMACEUTICAL COMPOSITION, USE OF THE HERPES VIRUS OR PHARMACEUTICAL COMPOSITION, METHOD FOR EXPRESSING, ENHANCED, INCREASING, MAGNIFYING AND/OR SUPPLEMENTING THE LEVELS OF AN IMMUNOMODULATORY POLYPEPTIDE, METHOD FOR PROVIDING AL PROPHYLACTIC IVIO, PALLIATIVE OR THERAPEUTIC, AND METHOD TO TREAT CANCER
CN113730576B (en) * 2021-08-31 2023-03-28 佛山市第一人民医院（中山大学附属佛山医院） Application of nano photo-thermal material in preparation of laser depilation drug
AU2024229184A1 (en) 2023-03-02 2025-08-28 Krystal Biotech, Inc. Interleukin-2 and interleukin-12 for cancer therapy
WO2024214081A1 (en) 2023-04-13 2024-10-17 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
US6268222B1 (en) * 1998-01-22 2001-07-31 Luminex Corporation Microparticles attached to nanoparticles labeled with flourescent dye
US6424857B1 (en) * 1997-06-16 2002-07-23 Amersham Health As Use of acousto-optical and sonoluminescene contrast agents
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US6602932B2 (en) * 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267235A (en) * 1979-03-19 1981-05-12 California Institute Of Technology Polyglutaraldehyde microspheres
US5073498A (en) * 1984-12-24 1991-12-17 Caribbean Microparticles Corporation Fluorescent alignment microbeads with broad excitation and emission spectra and its use
US5395688A (en) * 1987-10-26 1995-03-07 Baxter Diagnostics Inc. Magnetically responsive fluorescent polymer particles
US5437274A (en) * 1993-02-25 1995-08-01 Gholam A. Peyman Method of visualizing submicron-size vesicles and particles in blood circulation
US6592847B1 (en) * 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6695870B2 (en) * 2002-02-25 2004-02-24 Nanocomp, L.L.C. Process for treating disease
US6964747B2 (en) * 2003-01-21 2005-11-15 Bioarray Solutions, Ltd. Production of dyed polymer microparticles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214560B1 (en) * 1996-04-25 2001-04-10 Genicon Sciences Corporation Analyte assay using particulate labels
US6424857B1 (en) * 1997-06-16 2002-07-23 Amersham Health As Use of acousto-optical and sonoluminescene contrast agents
US6268222B1 (en) * 1998-01-22 2001-07-31 Luminex Corporation Microparticles attached to nanoparticles labeled with flourescent dye
US6602932B2 (en) * 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform

Also Published As

Publication number Publication date
CA2516116A1 (en) 2004-08-05
WO2004064751A2 (en) 2004-08-05
EP1583473A2 (en) 2005-10-12
US20070148074A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2004064751A3 (en) Nanoparticle based stabilization of ir fluorescent dyes
WO2000071162A3 (en) Cyanine and indocyanine dye bioconjugates for biomedical applications
Lee et al. Near‐infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution
Wang et al. Responsive polymer–fluorescent carbon nanoparticle hybrid nanogels for optical temperature sensing, near-infrared light-responsive drug release, and tumor cell imaging
WO2006010083A3 (en) Biodegradable nanoparticles
KR101557973B1 (en) Polymer nanoparticles containing ultraviolet blocking substance and method for producing the same
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2003087165A3 (en) Biocompatible materials and probes
WO2005089106A3 (en) Degradable nanoparticles
EP2530157A3 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CN113876600B (en) Detection and treatment of caries and microcavities with nanoparticles
US12152182B2 (en) Polymer nanoparticles for afterglow molecular imaging
EP1921132A3 (en) Laundry treatment composition
EP2609935A1 (en) Switching fluorescent nanoparticle probe and fluorescent particle imaging method using same
WO2010096733A2 (en) Luminescent porous silicon nanoparticles, methods of making and using same
CN107652967B (en) Auto-fluorescent polyacrylamide nano particle and preparation method and application thereof
CN110542671B (en) Organic two-photon fluorescent probe, preparation and application thereof
WO2007077531A8 (en) Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof
Albers et al. Self‐Assembled (Aza) BODIPY Dyes for Biomedical in Vivo Imaging
WO2002078611A3 (en) Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
KR20100005589A (en) Hyaluronic acid immobilized gold nanoparticles for detection of reactive oxygen species and preparing method thereof
AU2001232818A1 (en) Hydrophilic cyanine dyes
JP2000355533A5 (en)
CN102432755A (en) Multi-targeted photodynamic therapy polymer carrier and preparation method thereof
WO2004048601A3 (en) Modulation of b7h expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004702592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2516116

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20048054256

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004702592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007148074

Country of ref document: US

Ref document number: 10542185

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10542185

Country of ref document: US